stockportfolio.pro
Crinetics Pharmaceuticals, Inc. (CRNX)
Healthcare · Biotechnology · NasdaqGS
Crinetics Pharmaceuticals, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $589,000 | $2.04M | $2.43M | $1.19M | $71,000 | $1.08M | $4.74M | $4.01M | $1.04M | $7.70M |
| Gross profit | — | — | — | — | — | — | — | $4.01M | $1.04M | $6.62M |
| Net income | $-6.02M | $-9.16M | $-27.11M | $-50.42M | $-73.81M | $-107.64M | $-163.92M | $-214.53M | $-298.41M | $-465.32M |
| Net margin | -1021.9% | -447.8% | -1116.8% | -4226.5% | -103960.6% | -9985.3% | -3460.4% | -5345.9% | -28720.7% | -6046.2% |
Source: Crinetics Pharmaceuticals, Inc. SEC filings (10-K).
Explore 10 years of Crinetics Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CRNX in your portfolio →
Crinetics Pharmaceuticals, Inc. financial history by metric
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Crinetics Pharmaceuticals, Inc. — frequently asked questions
What is Crinetics Pharmaceuticals, Inc.'s revenue?
Crinetics Pharmaceuticals, Inc. (CRNX) reported revenue of $7.70M for fiscal year 2025, up 640.7% from the prior year, according to its SEC filings.
Is Crinetics Pharmaceuticals, Inc. profitable?
No — CRNX reported a net loss of $-465.32M in fiscal 2025.
What is CRNX's P/E ratio?
Crinetics Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Crinetics Pharmaceuticals, Inc. growing?
CRNX's revenue grew at roughly 155.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Crinetics Pharmaceuticals, Inc. have?
As of fiscal year 2025, CRNX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Crinetics Pharmaceuticals, Inc.'s gross margin?
CRNX's gross margin was 86.0% in fiscal 2025 — gross profit of $6.62M on revenue of $7.70M.
What is Crinetics Pharmaceuticals, Inc.'s market cap?
Crinetics Pharmaceuticals, Inc. (CRNX) has a market capitalization of about $3.52B, based on the latest data in our nightly-refreshed cache.
When does Crinetics Pharmaceuticals, Inc.'s fiscal year end?
CRNX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Crinetics Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 10 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.